Payment overview · 2025
General Payments
$1,415.17
45 reported records · 14 companies
Healthcare provider profile · identity verified
Mazen Alsaqa, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STERLING HEIGHTS, MI · NPI 1982968244
Verified facts
What the public records show
CMS Open Payments records show Mazen Alsaqa, M.D. received $1,415.17 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $423.94 | 30.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $213.64 | 15.1% | 7 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.22 | 9.7% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $113.18 | 8.0% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $111.71 | 7.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $109.44 | 7.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $105.74 | 7.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.63 | 4.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.13 | 3.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.54 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.93 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.92 | 1.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.41 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.74 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,415.17 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $299.20 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $213.64 | 7 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $137.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $131.08 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $113.18 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $113.18 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $111.71 | 4 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $111.71 | 4 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $111.71 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $105.74 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.99 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.99 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $67.08 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.56 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.13 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 110 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 306 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 53 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1025 | 189 |
| Metformin Hcl | Metformin Hcl | 629 | 109 |
| Omeprazole | Omeprazole | 610 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 593 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 96 |
| Losartan Potassium | Losartan Potassium | 510 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 66 |
| Lisinopril | Lisinopril | 381 | 75 |
| Simvastatin | Simvastatin | 349 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 327 | 78 |
| Tradjenta | Linagliptin | 325 | 42 |
| Jardiance | Empagliflozin | 306 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 55 |
| Gabapentin | Gabapentin | 225 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 40 |
| Furosemide | Furosemide | 206 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 42 |
| Famotidine | Famotidine | 198 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 177 | 56 |
| Montelukast Sodium | Montelukast Sodium | 165 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 159 | 43 |
| Linzess | Linaclotide | 153 | 21 |
| Meclizine Hcl | Meclizine Hcl | 147 | 39 |
| Azithromycin | Azithromycin | 145 | 105 |
| Glipizide | Glipizide | 145 | 25 |
| Allopurinol | Allopurinol | 143 | 23 |
| Sertraline Hcl | Sertraline Hcl | 142 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 141 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 44 |
| Januvia | Sitagliptin Phosphate | 132 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 24 |
| Alprazolam | Alprazolam | 127 | 23 |
| Prednisone | Prednisone | 126 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 28 |
| Valsartan | Valsartan | 122 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 63 |
| Carvedilol | Carvedilol | 119 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 18 |
| Hydrocortisone | Hydrocortisone | 117 | 29 |
| Ibuprofen | Ibuprofen | 116 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 21 |
| Eliquis | Apixaban | 110 | 24 |
| Naproxen | Naproxen | 108 | 39 |
| Ezetimibe | Ezetimibe | 106 | 13 |
| Lidocaine | Lidocaine | 106 | 22 |
| Atenolol | Atenolol | 104 | 23 |
| Donepezil Hcl | Donepezil Hcl | 104 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 20 |
| Xarelto | Rivaroxaban | 99 | 15 |
| Vascepa | Icosapent Ethyl | 94 | 11 |
| Chlorthalidone | Chlorthalidone | 92 | 15 |
| Pregabalin | Pregabalin | 92 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 23 |
| Ketoconazole | Ketoconazole | 83 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 16 |
| Alendronate Sodium | Alendronate Sodium | 78 | 15 |
| Tramadol Hcl | Tramadol Hcl | 71 | 26 |
| Potassium Chloride | Potassium Chloride | 70 | 14 |
| Rybelsus | Semaglutide | 68 | suppressed |
| Myrbetriq | Mirabegron | 63 | 16 |
| Ozempic | Semaglutide | 62 | 12 |
| Farxiga | Dapagliflozin Propanediol | 61 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 61 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 58 | suppressed |
| Memantine Hcl | Memantine Hcl | 57 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 12 |
| Meloxicam | Meloxicam | 55 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 47 |
| Lovastatin | Lovastatin | 53 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 53 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 49 | 12 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 48 | 22 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 47 | 18 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Invokana | Canagliflozin | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 43 | suppressed |
| Nystatin | Nystatin | 42 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 38 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 29 |
| Prolia | Denosumab | 36 | 23 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 21 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 30 | suppressed |
| Lactulose | Lactulose | 30 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 30 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Ibu | Ibuprofen | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 21 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 17 |
| Ondansetron Odt | Ondansetron | 20 | 19 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Erythromycin | Erythromycin Base | 18 | 15 |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 16 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fluorometholone | Fluorometholone | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,415.17 · 45 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Flexitouch Plus, GEMTESA, GLYCATE, JARDIANCE, KISUNLA, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PYRUKYND, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, TRELEGY ELLIPTA, ZAVZPRET, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error